CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Sanofi (SNY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Sanofi (SNY)

Pharmaceutical Preparations · market cap $50.8B · as of 2026-10-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-25 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Sanofi is a Paris-headquartered multinational pharmaceutical company with roughly 82,900 employees. At ~$40.29 its US-listed shares (SNY) imply a market cap of ~$49.1B in our data, against 2025 net income of $7.85B and R&D spend of $7.84B. Our data lists efanesoctocog alfa (BIVV001) in hemophilia A as the lead asset at Phase 3. The near-term calendar is dense, led by a venglustat PDUFA date (2026-11-25), Phase 3 readouts for PCV21 and mometasone furoate nasal spray, and Q3 earnings on 2026-10-30.
The catalyst path
  • 2026-11-25 (est.)Phase 3 · Rilzabrutinibimp 9/10
  • 2026-11-25PDUFA · Venglustatimp 9/10
  • 2026-11-28 (est.)Phase 3 · Measles, combinations with mumps and rubella, live attenuatedimp 9/10
  • 2026-12-01 (est.)Phase 2 · Pandemic flu H5 HA mRNA SD2 vaccineimp 7/10
  • 2026-12-01 (est.)Phase 3 · PCV21imp 9/10
  • 2026-12-17 (est.)Phase 2 · SAR442970imp 7/10
  • 2026-12-23 (est.)Phase 2 · Frexalimabimp 7/10
  • 2026-12-31 (est.)Phase 2 · Isatuximabimp 7/10
Pipeline
AssetPhaseIndication
SR147778Phase 2Obesity
XRP0038 (NV1FGF)Phase 2Peripheral Arterial Disease
efanesoctocog alfa (BIVV001)Phase 3Hemophilia A
DuvakitugPhase 3Ulcerative Colitis
xaliproden (SR57746A)Phase 3Alzheimer Disease
zolpidem-MR (SL800750)Phase 3Sleep Initiation and Maintenance Disorders
A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3Influenza
CYD dengue vaccine serotypes (1, 2, 3, 4)Phase 2Dengue Virus
lactoserumPhase 3Hygiene
DTaP-IPV-HB-PRP~TPhase 3Diphtheria
Yellow fever vaccine (live)Phase 3Yellow Fever Immunization
G-CSF Plus PlerixaforPhase 2Hodgkin's Disease
SAR443122Phase 2Colitis Ulcerative
Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virusPhase 3Dengue
epidoxorubicine, ciclophosphamide, methotrexate, fluorouracilePhase 3Breast Neoplasms
Low Dose (LD) RSVt vaccinePhase 3RSV Immunisation
Insulin glargine/lixisenatide fixed ratio combinationPhase 3Type 2 Diabetes Mellitus
RSV vaccine candidatePhase 2Respiratory Syncytial Virus Infection
FexofenadinePhase 3Seasonal Allergic Rhinitis
rimonabant (SR141716)Phase 3Obesity
Price & technical context
3-month
+8.1%
6-month
+11.7%
12-month
-7.1%
52-wk range
$39.12–$52.14
vs 50-day MA
+13.7%
vs 200-day MA
+9.6%
Realized vol
24.1%
Max drawdown
-34.2%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SNY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.